Sign in to view content

What Happens to Diabetic Retinopathy Severity Scores With Less Aggressive Treatment? A Post Hoc Analysis of the RISE and RIDE Open Label Extension Study

Roger A. Goldberg, MD, MBA

Video
Published 2019

Roger A. Goldberg, MD, MBA, interviewed by Ratimir Lazic, MD, PhD

Related

Continuous submicrogram fluocinolone acetonide (FAc) therapy for the treatment of diabetic retinopathy
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2017
Episode 11: Endophthalmitis after Intravitreal Anti-VEGF Injections with Dr. David Almeida
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018
The Average Patient Does Not Enter Your Office: What Can We Learn About Treating nAMD From Individual Patient Responses
David S. Boyer, MD
Annual Meeting Talks
2019

Category: Diabetic Retinopathy

See more